Table 3 Comparison of serious adverse events between the advanced and non-advanced idiopathic pulmonary fibrosis groups
From: Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis
Characteristic | Total | Advanced | Non-advanced | P-value |
|---|---|---|---|---|
Number of patients | 108 | 51 | 57 | |
Serious adverse events | 59 (54.6) | 32 (62.7) | 27 (47.4) | 0.109 |
Pneumonia | 30 (27.8) | 16 (31.4) | 14 (24.6) | 0.430 |
Acute exacerbation | 9 (8.3) | 5 (9.8) | 4 (7.0) | 0.732 |
Pneumothorax | 6 (5.6) | 5 (9.8) | 1 (1.8) | 0.098 |
Lung cancer | 4 (3.7) | 1 (2.0) | 3 (5.3) | 0.620 |
Pulmonary thromboembolism | 3 (2.8) | 1 (2.0) | 2 (3.5) | 1.000 |
Cardiac disordersa | 3 (2.8) | 1 (2.0) | 2 (3.5) | 1.000 |
Cerebral vascular disease | 1 (0.9) | 1 (2.0) | 0 (0.0) | 0.472 |
Death | 18 (16.7) | 11 (21.6) | 7 (12.3) | 0.196 |
Pneumonia | 10 (9.3) | 7 (13.7) | 3 (5.3) | 0.186 |
Acute exacerbation | 2 (1.9) | 0 (0.0) | 2 (1.9) | 0.497 |
Severe liver injuryb | 1 (0.9) | 0 (0.0) | 1 (1.8) | 1.000 |
Cancer progression | 1 (0.9) | 1 (2.0) | 0 (0.0) | 0.472 |
Myocardial infarction | 1 (0.9) | 0 (0.0) | 1 (1.8) | 1.000 |
Unknown | 3 (2.8) | 1 (2.0) | 2 (3.5) | 1.000 |